ストックスクリーナーアプリを入手
16.70
1.74%
0.285
前日終値:
$16.42
開ける：
$16.66
24時間の取引高:
1.96M
Relative Volume:
0.70
時価総額：
$2.75B
収益：
-
当期純損益:
$-412.89M
株価収益率:
-4.3277
EPS:
-3.86
ネットキャッシュフロー:
$-361.93M
1週間 パフォーマンス:
-5.99%
1か月 パフォーマンス:
-14.55%
6か月 パフォーマンス:
+79.05%
1年 パフォーマンス:
+13.10%
1日の値動き範囲:
$16.40
$17.24
1週間の範囲:
$16.30
$17.88
52週間の値動き範囲:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
DYN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
16.70 | 2.70B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9%Here's What Happened - MarketBeat
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story? - simplywall.st
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Insider Monkey
DYN: Transformative clinical data and commercial launches planned for 2026–2027 in DMD and DM1 - TradingView — Track All Markets
DYN: Transformative DMD and DM1 therapies advance toward 2027 launches, backed by validated platform - TradingView — Track All Markets
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Why Dyne Therapeutics Inc stock appeals to analystsEarnings Risk Report & Risk Managed Investment Signals - Bộ Nội Vụ
Fed Meeting: Why Dyne Therapeutics Inc stock attracts high net worth investorsLong Setup & Long-Term Safe Investment Plans - Bộ Nội Vụ
Aug Gainers: Why Dyne Therapeutics Inc stock is trending among retail tradersTrade Ideas & Real-Time Sentiment Analysis - moha.gov.vn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Investing News Network
Downgrade Watch: Can Dyne Therapeutics Inc weather a recessionTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - Investing News Network
Day Trade: What is Dyne Therapeutics Incs 5 year growth outlookMarket Trend Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
(DYN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How risky is Dyne Therapeutics Inc. stock now2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Why hedge funds are buying Dyne Therapeutics Inc. stockJuly 2025 Market Mood & Detailed Earnings Play Strategies - ulpravda.ru
$350 million fundraise shows potential of novel DMD therapy - The Pharma Letter
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6%Here's What Happened - MarketBeat
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus - TechStock²
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7%What's Next? - MarketBeat
Liquidity Mapping Around (DYN) Price Events - Stock Traders Daily
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics Earnings Notes - Trefis
Free cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Free cash flow per share of Dyne Therapeutics, Inc. – BOATS:DYN - TradingView — Track All Markets
CapEx per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Operating cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
First Week of February 2026 Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
DYN (Dyne Therapeutics) EV-to-OCF : -7.12 (As of Dec. 27, 2025) - GuruFocus
Why analysts see a huge upside for Dyne Therapeutics (DYN) - MSN
Dyne Therapeutics (DYN): Valuation Check After Board Addition Signals Next Phase of Commercial Growth - Sahm
Dyne Therapeutics appoints Vikram Karnani to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
Dyne Therapeutics (DYN): Reaffirmed Buy Ratings Prompt Fresh Look at Valuation After Neuromuscular Data Update - Yahoo Finance
Dyne Therapeutics appoints Vikram Karnani to board of directors - Investing.com
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Deep Dive Into Its 87% Potential Upside - DirectorsTalk Interviews
Dyne Therapeutics Appoints Vikram Karnani to Board - TipRanks
Dyne Therapeutics appoints Vikram Karnani to board - MSN
Dyne Therapeutics Appoints Vikram Karnani as Independent Director - TradingView — Track All Markets
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors to Support Commercialization Efforts - Quiver Quantitative
Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors - TradingView — Track All Markets
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) - Finviz
Dyne Therapeutics (DYN) Price Target Increased by 12.57% to 39.97 - Nasdaq
Dyne Therapeutics, Inc. $DYN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - news.stocktradersdaily.com
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
4.73%
0.92%
大文字化:
|
ボリューム (24 時間):